IRIS Accounts Production v26.1.0.640 03011929 Board of Directors 1.1.25 31.12.25 31.12.25 8/5/26 false true false false true false Auditors Opinion Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh030119292024-12-31030119292025-12-31030119292025-01-012025-12-31030119292023-12-31030119292024-01-012024-12-31030119292024-12-3103011929ns15:EnglandWales2025-01-012025-12-3103011929ns14:PoundSterling2025-01-012025-12-3103011929ns10:Director12025-01-012025-12-3103011929ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3103011929ns10:SmallEntities2025-01-012025-12-3103011929ns10:Audited2025-01-012025-12-3103011929ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3103011929ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3103011929ns10:AbridgedAccounts2025-01-012025-12-3103011929ns10:OrdinaryShareClass12025-01-012025-12-3103011929ns10:Director22025-01-012025-12-3103011929ns10:Director32025-01-012025-12-3103011929ns10:Director42025-01-012025-12-3103011929ns10:Director52025-01-012025-12-3103011929ns10:RegisteredOffice2025-01-012025-12-3103011929ns5:CurrentFinancialInstruments2025-12-3103011929ns5:CurrentFinancialInstruments2024-12-3103011929ns5:ShareCapital2025-12-3103011929ns5:ShareCapital2024-12-3103011929ns5:RetainedEarningsAccumulatedLosses2025-12-3103011929ns5:RetainedEarningsAccumulatedLosses2024-12-3103011929ns10:OrdinaryShareClass12025-12-3103011929ns10:OrdinaryShareClass12024-01-012024-12-31
REGISTERED NUMBER: 03011929 (England and Wales)














Financial Statements

for the Year Ended 31st December 2025

for

Wolf Laboratories Limited

Wolf Laboratories Limited (Registered number: 03011929)






Contents of the Financial Statements
for the year ended 31st December 2025




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 3


Wolf Laboratories Limited

Company Information
for the year ended 31st December 2025







DIRECTORS: N. A. Bewell
D. J. Child
J. A. Foss
D. A. Suddaby
I. A. Roulstone



REGISTERED OFFICE: Colenso House
1 Deans Lane
Pocklington
YO42 2PX



REGISTERED NUMBER: 03011929 (England and Wales)



AUDITORS: Sadofskys
Statutory Auditors
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX



BANKERS: Natwest Bank Plc
60-61 Saturday Market
Beverley
HU17 8AA

Wolf Laboratories Limited (Registered number: 03011929)

Abridged Balance Sheet
31st December 2025

2025 2024
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 169,438 146,675

CURRENT ASSETS
Stocks 429,312 390,134
Debtors 2,154,864 3,120,249
Cash at bank and in hand 1,765,323 1,320,052
4,349,499 4,830,435
CREDITORS
Amounts falling due within one year 2,135,844 2,623,520
NET CURRENT ASSETS 2,213,655 2,206,915
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,383,093

2,353,590

PROVISIONS FOR LIABILITIES 41,782 35,794
NET ASSETS 2,341,311 2,317,796

CAPITAL AND RESERVES
Called up share capital 5 40,000 40,000
Retained earnings 2,301,311 2,277,796
SHAREHOLDERS' FUNDS 2,341,311 2,317,796

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 31st December 2025 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 8th May 2026 and were signed on its behalf by:





N. A. Bewell - Director


Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements
for the year ended 31st December 2025

1. STATUTORY INFORMATION

Wolf Laboratories Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Significant judgements and estimates
In the application of the company's accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on the directors historical experience and knowledge as well as other factors which may be considered relevant, as a result the actual results may differ from these estimates.

The estimates and underlying assumptions applied are reviewed by the directors on an ongoing basis.

Revisions to these accounting estimates are recognised in the period to which the revisions have been revised where these revisions affect only that period, or in the period of revision and future period where this revision would affect both current and future periods.

No key sources of estimation uncertainty are noted by management that have a significant effect on the amounts recognised in the financial statements.

Turnover
(i) Sale of goods and materials: Income for the sale of goods and materials is recognised when goods are delivered or used and legal title of the goods supplied has been passed to the customer, sales are made on a credit basis. The amounts reported are net of VAT and trade discounts.

(ii) Interest Income: Interest income is recognised using the effective interest rate method.

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2025

2. ACCOUNTING POLICIES - continued

Property, plant and equipment
Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses.

Depreciation is provided on all property, plant and equipment, at rates calculated to write off the cost less estimated residual value, of each item on a systematic basis over their expected useful lives as follows:

Plant and machinery etc - 25% on cost

Assets held under hire purchase agreements of finance leases are depreciated in the same way as owned assets.

At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of the asset, the company estimates the recoverable amount of the cash-generating unit to which the assets belong.

Stock
Stock is stated at the lower of cost and estimated selling price less costs to sale. Inventories are recognised as an expenses in the period in which the related revenue is recognised.

Cost includes all costs of the purchases, costs of conversion and other costs incurred in bringing stock to its present location and condition. Provision is made for damaged, obsolete and slow moving stock where appropriate.

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2025

2. ACCOUNTING POLICIES - continued

Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial statements.

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

Taxation
Taxation expenses for the year comprises current and deferred tax recognised in the reporting period. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax represents the amount of tax payable or receivable in respect of the taxable profit (or loss) for the current or past reporting periods. It is measured at the amount expected to be paid or recovered using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Transactions in currencies, other than the functional currency of the company, are recorded are the rate of exchange on the date the transaction occurs. Monetary items denominated in other currencies are translated the rate of exchange prevailing at the end of the reporting period. Exchange differences are taken into account in arriving at the operating result. Non-monetary items that are measured at historic cost in a foreign currency are not retranslated.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Short-term employee benefits are recognised as an expense on the period they are incurred.

Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

Debtors and creditors receivable/payable within one year
i) Trade and other debtors:

Short term trade and other debtors are initially measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transactions costs and are measured subsequently at amortised costs using the effective interest method, less any impairment.

ii) Trade and other creditors:

Short term trade and other creditors are initially measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 28 (2024 - 30 ) .

Wolf Laboratories Limited (Registered number: 03011929)

Notes to the Financial Statements - continued
for the year ended 31st December 2025

4. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1st January 2025 298,777
Additions 93,658
At 31st December 2025 392,435
DEPRECIATION
At 1st January 2025 152,102
Charge for year 70,895
At 31st December 2025 222,997
NET BOOK VALUE
At 31st December 2025 169,438
At 31st December 2024 146,675

5. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: £    £   
40,000 Ordinary £1 40,000 40,000

6. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Alan Brocklehurst (Senior Statutory Auditor)
for and on behalf of Sadofskys

7. ULTIMATE PARENT AND CONTROLLING PARTY

The ultimate controlling party is LBO France, a company registered in France (RCS Strasbourg Reg. No. 418354502). The immediate parent company is Flow Group Holdings Limited, a company registered in England and Wales (Reg. No. 11869393).

The parent of the largest group for which consolidated financial statements are drawn up is Dutscher Holding. Copies of the consolidated accounts can be obtained from 2C, Rue De Bruxelles, 67170, Bernolsheim, France.

The parent of the smallest group for which consolidated financial statements are drawn up is Scientific Laboratory Supplies Group Limited, whose registered office address is Orchard House, The Square, Hessle, United Kingdom, HU13 0AE.

Dutscher Holding SAS (incorporated in France) is regarded by the directors as being the company's ultimate parent company (RCS Strasbourg Reg. No. 882634660).